ARCT

#2960
Arcturus Therapeutics Holdings Inc. Common Stock
8.23
-0.84%
Secteur:
Base:
Devise de Profit:
Range quotidien
8.23
8.23
Range Annuel
5.86
24.14
Changement quotidien
-0.84%
Changement Mensuel
+9.73%
Evolution sur 6 mois
-51.87%
Changement Annuel
-48.50%
Clôture Précédente
8.30
Open
8.23
Bid
Ask
Low
8.23
High
8.23
Volume
80
Open full chart

Financials

Overview Relevé Statistics Dividends
Quarterly Annual
  • Market Capitalization 223.76 M
  • Employee 176
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-7.52
Price to sales ratio
5.12
Dividends per share
—
Dividend yield %
—

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Nouvelles